Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.

@article{Green2005WeeklyPI,
  title={Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.},
  author={Marjorie C. Green and Aman U. Buzdar and Terry L. Smith and Nuhad K Ibrahim and Vicente Valero and Marguerite F Rosales and Massimo Cristofanilli and Daniel J. Booser and Lajos Pusztai and Edgardo D. Rivera Rivera and Richard L. Theriault and Cynthia Carter and Debra K. Frye and Kelly K. Hunt and William Fraser Symmans and Eric A Strom and Aysegul A. Sahin and William M Sikov and Gabriel N. Hortobagyi},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 25},
  pages={
          5983-92
        }
}
PURPOSE To determine the impact a change in schedule of paclitaxel administration from once every 3 weeks to frequent administration would have on the pathologic complete response (pCR) rate in the breast and lymph nodes for patients with invasive breast cancer treated with primary systemic chemotherapy (PST). PATIENTS AND METHODS Patients with clinical stage I-IIIA breast cancer were randomly assigned to receive PST of paclitaxel doses administered either weekly (for a total of 12 doses of… Expand
Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study.
TLDR
Neoadjuvant chemotherapy by weekly paclitaxel and cisplatin combination was highly effective and tolerated in this study, especially in the triple negative and HER2 positive tumors. Expand
Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer
TLDR
Under the condition of same cumulative doses, weekly paclitaxel was more effective than 3 weeks schedule in terms of pathologic response to primary chemotherapy in breast cancer, and caused more treatment delay related to toxicity though well tolerant. Expand
Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.
  • W. Sikov, D. Dizon, +6 authors M. Fenton
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
Neoadjuvant carboplatin and weekly paclitaxel +/- trastuzumab achieve high pCR rates in patients with HER2-positive and triple-negative disease without exposure to an anthracycline. Expand
Single agent weekly paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a feasibility study.
TLDR
The regimen of weekly single agent paclitaxel with a pathological response rate that was comparable with other regimens in this group of advanced stage patients is feasible in patients with locally advanced breast cancer with acceptable toxicity. Expand
Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer.
TLDR
The pathological complete response (pCR) rate was significantly higher in those patients with estrogen receptor (ER)- and progesterone receptor (PR)-negative tumors and inThose patients who completed the treatment course. Expand
Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer
TLDR
Tumor proliferation at baseline and response to chemotherapy as measured by mitotic activity may serve as an important indicator of pathologic response to neoadjuvant paclitaxel/radiation. Expand
Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule.
TLDR
A more frequent administration might improve the possibility of eradicating invasive cancer in the breast and axilla, especially in the luminal-B (HER2-positive) subtype. Expand
Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study
TLDR
Neoadjuvant AC followed by weekly docetaxel is a feasible regimen for patients with early-stage breast cancer. Expand
Phase II Trial in Japan of Sequential Administration of Weekly Paclitaxel Followed by FEC as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer [KBCSG0206 Trial: Kinki Breast Cancer Study Group (KBCSG)]
Objective: We conducted a phase II trial in Japan to evaluate the efficacy and tolerability of weekly paclitaxel followed by fluorouracil, epirubicin, and cyclophosphamide (FEC) as neoadjuvantExpand
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
BACKGROUND A dose-dense weekly schedule of paclitaxel (resulting in a greater frequency of drug delivery) plus carboplatin every 3 weeks or the addition of bevacizumab to paclitaxel and carboplatinExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
  • I. Henderson, D. Berry, +16 authors L. Norton
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
TLDR
The addition of four cycles of paclitaxel after the completion of a standard course of CA improves the disease-free and overall survival of patients with early breast cancer. Expand
Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.
TLDR
Objective responses have been seen in 12 of 14 assessable patients, including six with MBC (one complete response, five partial responses) and six with LABC (two complete responses, four partial responses), for an overall response rate of 86% (95% confidence interval, 66% to 96%). Expand
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
TLDR
Preliminary results suggest that the addition of paclitaxel to a FAC regimen of adjuvant or neoadjuvant therapy may further reduce the risk of disease recurrence; however, differences were not statistically significant. Expand
Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer.
TLDR
Weekly paclitaxel therapy was well tolerated and demonstrated reasonable activity in this relatively heavily pretreated population with advanced disease, and further study of weekly pac litaxel in combination therapy is warranted. Expand
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
  • A. Seidman, C. Hudis, +8 authors L. Norton
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
TLDR
Therapy was well tolerated and remarkable for a lack of overall and cumulative myelosuppression in patients with metastatic breast cancer and should be incorporated into future comparative clinical trials. Expand
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
TLDR
The addition of PTX to AC resulted insignificant improvement in DFS but no significant improvement in OS with acceptable toxicity, and toxicity with the AC --> PTX regimen was acceptable for the adjuvant setting. Expand
Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.
  • J. Abrams, D. Vena, +7 authors M. Friedman
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1995
TLDR
Paclitaxel's activity in this multiinstitutional trial in heavily pretreated patients confirms the encouraging results attained in single-institution trials. Expand
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
  • H. Bear, S. Anderson, +8 authors N. Wolmark
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
TLDR
The addition of four cycles of preoperative docetaxel after four cyclesof preoperative AC significantly increased clinical and pathologic response rates for operable breast cancer. Expand
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
  • M. Citron, D. Berry, +18 authors L. Norton
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
TLDR
Dose density improves clinical outcomes significantly, despite the lower than expected number of events at this time, and Sequential chemotherapy is as effective as concurrent chemotherapy. Expand
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.
TLDR
The results of this trial substantiate the activity of paclitaxel in the treatment of MBC and suggest a dose-effect relationship. Expand
...
1
2
3
...